Burden and unmet need for specialist care in poorly controlled and severe childhood asthma in a Danish nationwide cohort

• Published in: Respiratory research 2023-06, Vol.24 (1), p.173-173, Article 173
• Main Authors: Håkansson, Kjell Erik Julius, Guerrero, Silvia Cabrera, Backer, Vibeke, Ulrik, Charlotte Suppli, Rastogi, Deepa
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adolescent; Adolescents; Adrenal Cortex Hormones - therapeutic use; Age groups; Anti-Asthmatic Agents - therapeutic use; Asthma; Asthma - diagnosis; Asthma - drug therapy; Asthma - epidemiology; Asthma in children; Bronchodilator Agents; Bronchodilators; Care and treatment; Child; Childhood; Children; Childrens health; Codes; Corticoids; Corticosteroids; Denmark - epidemiology; Development and progression; Diagnosis; Disease control; Drug dosages; Exacerbations; Female; Health care; Humans; Male; Medical records; Paediatric asthma; Pediatrics; Population cohort; Primary care; Quality of life; Risk; Steroid hormones; Steroids; Teenagers
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/s12931-023-02482-7

Asthma is a common disease in childhood and adolescence with lifelong consequences particularly among those at risk of severe disease, poor control and/or frequent exacerbations. Specialist care is recommended for at-risk children and adolescents, yet access to specialist management in free-to-access healthcare settings remains poorly understood. A Danish nationwide cohort of children and adolescents aged 2-17 years with persistent asthma, defined as repeated redemption of inhaled corticosteroids (ICS) during 2015, were followed for two years, to identify at-risk children and adolescents comprising those with severe asthma (classified according to GINA 2020 guidelines), poor control (defined as use of 400/600 (ages 2-11/12 +) annual doses of short-acting bronchodilators), or frequent exacerbations (defined as use of oral steroids or hospitalization), and access to specialist care. The population is chosen due to detailed medical records in the setting of universal health care. The cohort comprised of 29,851 children and adolescents (59% boys), with a median age of 9 years. While 17% of children were on high dose ICS, 22% were on daily ICS below GINA low dose cut-off. Prevalence of severe asthma (3.0-6.5%) was lower than poor asthma control (6.4-25%); both declined from childhood to adolescence. Exacerbations occurred in 7.1-9.0% of children, with median number of exacerbations being 1 (IQR 1-1). Despite being classified as having mild-to-moderate asthma, 15% had poor asthma control and 3.8% experienced exacerbation(s), respectively. While 61% of children with severe asthma and 58% with exacerbation-prone disease were in specialist care, only 24% with uncontrolled disease were receiving specialist care. Of children and adolescents using high-dose ICS, 71% were managed in primary care, while the use of additional controllers was more common in specialist care. Throughout childhood and adolescence, there was a high prevalence of severe asthma and poor control, although their prevalence declined with age. We demonstrate a large unmet need for specialist care among children with at-risk asthma, particularly among those with poorly controlled asthma, even in a system with free-to-access, tax-funded healthcare.